

HEALTHCARE INDUSTRY Q3 2024 VALUATION UPDATE

2

2



# Table of Content

Industry Overview

**Global Comparable Public Companies** 

**Global Transactions** 

**About Seale** 





# Introduction

We are pleased to share our Healthcare Industry Multiples Valuation Update for Q3 2024.

At Seale & Associates, we are committed to providing process-driven solutions designed to optimize value and achieve our client's strategic objectives in a range of transactions, including Mergers, Acquisitions, Divestitures and Carve-Outs, Business Sales, Recapitalizations, and Joint Ventures, among other corporate finance and strategy consulting services.

Over the course of 25+ years, we have successfully served clients all over the world, and we are delighted to continue providing investment banking advisory services to our clients who are looking to grow through acquisitions or optimize their portfolios through strategic divestitures.

Seale has extensive experience advising leading multinational companies, private equity firms, and family-owned businesses across a wide range of industries.



James A. Seale | President jseale@sealeassociates.com



**Brett M. Carmel | Senior Managing Director** bcarmel@sealeassociates.com



**Robert Whitney | Managing Director** rwhitney@sealeassociates.com



**Sergio Garcia del Bosque | Managing Director** sgarcia@sealeassociates.com



**Carlos Hernández Goudet | Managing Director** chernandez@sealeassociates.com





Alejandro Montemayor | Vice President amontemayor@sealeassociates.com

Armando Rios | Vice President arios@sealeassociates.com



# Healthcare's Industry Overview, M&A Trends and Market Intelligence


### Healthcare M&A Trends and Market Intelligence

- The demand for innovative solutions, particularly in digital health, personalized medicine, and advanced diagnostics, remained strong, driven by patient-centric care models. Biotechnology and life sciences sectors continued to attract high valuations, with a growing emphasis on gene therapies and precision medicine, bolstering investor confidence
- **M&A activity** in the industry remained **strong**, with **strategic buyers** accounting for 90% of the transaction volume, while **financial buyers** represented the remaining **10%**
- Healthcare EBITDA multiples remained stable at historically elevated levels in Q3 2024, except for the **Biotechnology segment**, which saw rapid growth of 38.0% YTD, following a similar increase in 2023. In comparison, the S&P 500's multiple growth was 26.0% YOY
- **Political landscape introduced uncertainties**, **particularly** with the potential rollback of measures like expanded Medicaid and ACA subsidies, which had previously benefited hospitals. The appointment of figures with critical views on healthcare spending signaled **possible reductions in funding and increased** oversight for hospitals
- The sector saw a continued **focus on digital health** innovations, including telehealth services and Al-driven diagnostics. These advancements aimed to enhance patient care and operational efficiency, addressing some of the challenges posed by labor shortages and increasing demand for personalized medicine
- Healthcare services and technology companies face sharp valuation declines, with some shutting down despite cutting R&D and acquisition costs. This creates opportunities for strategic and PE investors to acquire talent and capabilities at favorable terms. Not-for-profit health systems, supported by past refinancing, can also diversify through timely acquisitions
- In summary, Q3 2024 was marked by a blend of growth opportunities and challenges within the healthcare industry. While financial performance and M&A activity indicated resilience, regulatory uncertainties and operational hurdles require strategic adaptations to maintain momentum

Source: Capital IQ, Wall Street Journal, McKinsey and Other Industry Reports

#### Healthcare Industry M&A Deal Size and Volume








# Pharmaceutical Producers Global Comparable Public Companies (1/3)

		Market	Enterprise	Revenue	EBITDA		Average BITDA	Third Qua Sep. 30, 2	
Company	Count	ry Cap. US\$M	Value US\$M	US\$M	Margin	2022	2023	EV/ EBITDA	E Rev
AbbVie Inc.	abbvie USA	\$348,818	\$406,642	\$55,533	47.6%	11.2x	10.5x	15.4x	7
Astellas Pharma Inc.	Tastellas JPN	\$20,614	\$25,428	\$12,370	15.7%	11.0x	10.3x	13.1x	2
AstraZeneca PLC	AstraZeneca 😒 GBR	\$240,782	\$269,050	\$51,206	33.6%	21.7x	14.7x	15.6x	5.
Bausch Health Companies Inc.	<b>BAUSCH</b> CAN	\$2,996	\$25,009	\$9,474	32.5%	8.3x	8.4x	8.1x	2.
Bristol-Myers Squibb Company	راله Bristol Myers Squibb USA	\$104,897	\$151,971	\$47,435	41.2%	8.9x	8.3x	7.8x	3.
Catalent, Inc.	Catalent. USA	\$10,991	\$15,690	\$4,422	12.4%	16.6x	17.0x	28.7x	3.
Daiichi Sankyo Company, Limited	🔘 Daiichi-Sankyo JPN	\$62,476	\$57,564	\$12,271	18.4%	46.8x	48.6x	25.5x	4
Eisai Co., Ltd.	Eisai JPN	\$10,550	\$9,868	\$5,257	9.5%	37.5x	49.5x	19.8x	٦.
GSK plc	gsk gbr	\$82,908	\$100,811	\$41,966	35.7%	8.8x	7.3x	6.7x	2.
Johnson & Johnson	Johnson-Johnson USA	\$390,118	\$406,134	\$87,696	35.6%	14.0x	12.6x	13.0x	4





# Pharmaceutical Producers Global Comparable Public Companies (2/3)

Company	Country	Market y Cap.	Enterprise Value	Revenue US\$M	Revenue EBITDA		Average BITDA	Third Quarte Sep. 30, 2024	
Company	Country	US\$M	US\$M	US\$M	Margin	2022	2023	EV/ EBITDA	E Revo
Merck & Co., Inc.	<b>MERCK</b> USA	\$287,853	\$314,353	\$63,174	37.9%	11.1x	12.6x	13.1x	5.
Novartis AG	U NOVARTIS CHE	\$232,847	\$254,894	\$49,940	41.0%	6.2x	10.5x	12.4x	5
Novo Nordisk A/S	DNK novo nordisk <sup>®</sup>	\$521,589	\$520,753	\$40,468	47.3%	25.1x	29.3x	27.2x	12
Otsuka Holdings Co., Ltd.	Otsuka JPN	\$30,549	\$29,202	\$15,842	21.3%	9.4x	7.9x	8.6x	1.
Pfizer Inc.	<b>Pfizer</b> USA	\$163,994	\$227,027	\$59,375	19.3%	7.6x	6.3x	19.8x	3.
Roche Holding AG	Roche CHE	\$257,624	\$294,672	\$71,718	35.2%	12.1x	9.8x	11.7x	4
Sanofi	sanofi FRA	\$143,853	\$163,106	\$54,032	24.7%	10.5x	9.1x	12.2x	3.
Shionogi & Co., Ltd.	SHIONOGI JPN	\$12,190	\$10,427	\$2,921	36.6%	19.7x	8.5x	9.7x	3.






















# Pharmaceutical Producers Global Comparable Public Companies (3/3)

		Market	Value	Revenue	EBITDA				l Quarte 30, 2024	
Company	Country	Cap. US\$M	Value US\$M	US\$M	Margin	2022	2023	EV/ EBITDA	E Rev	
Sun Pharmaceutical Industries Limited	SUN IND	\$55,196	\$53,718	\$6,007	26.4%	20.6x	21.5x	33.8x	8	
Takeda Pharmaceutical Company Limited	Takeda JPN	\$45,389	\$82,340	\$31,732	27.1%	8.6x	9.4x	9.6x	2	
Teva Pharmaceutical Industries Limited		\$20,417	\$37,285	\$16,772	28.0%	7.0x	7.4x	7.9x	2	
UCB SA	BEL	\$34,279	\$37,190	\$6,083	21.7%	11.2x	14.1x	28.1x	6	
Excluded from mean and median					Mean	10.7x	10.3x	12.0x	3.	
					Median	11.2x	10.4x	13.1x	3	





# Medical Devices & Consumables Global Comparable Public Companies (1/2)

Company	Count	Market	Enterprise	Revenue	EBITDA	Annual A EV/EB		Third ( Sep. 30	Ŭ
Company	Countr	y Cap. US\$M	Value US\$M	US\$M	Margin	2022	2023	EV/ EBITDA	E Reve
Ansell Limited	Ansell Aus	\$3,191	\$3,149	\$1,619	16.4%	8.0x	8.8x	11.9x	1.'
Baxter International Inc.	<b>Baxter</b> USA	\$19,371	\$30,684	\$15,062	20.3%	14.8x	10.8x	10.0x	2.
Becton, Dickinson and Company	<b>BD</b> USA	\$69,688	\$83,701	\$19,828	26.5%	16.1x	17.7x	15.9x	4.
Boston Scientific Corporation	Scientific USA	\$123,406	\$131,667	\$15,911	25.4%	20.9x	24.4x	32.5x	8.
Cardinal Health, Inc.	CardinalHealth <sup>™</sup> USA	\$26,742	\$27,113	\$224,454	1.3%	7.8x	9.2x	9.0x	0
ConvaTec Group PLC	GBR	\$6,227	\$7,622	\$2,200	22.6%	15.8x	15.2x	15.3x	3.
Edwards Lifesciences Corporation	E Edwards Lifesciences USA	\$39,752	\$38,523	\$6,315	32.6%	32.9x	25.2x	18.7x	6
Hogy Medical Co.,Ltd.	HOGY. JPN	\$702	\$595	\$273	27.0%	7.3x	6.7x	8.1x	2.
ICU Medical, Inc.	icumedical USA	\$4,451	\$5,805	\$2,340	12.3%	21.5x	18.4x	20.1x	2.
JMS Co.,Ltd.	JPN	\$85	\$198	\$474	5.9%	6.2x	6.8x	7.1x	Ο.

























# Medical Devices & Consumables Global Comparable Public Companies (2/2)

Company		Souptry	Market	Enterprise Value	Revenue	EBITDA		Average BITDA	Third Quarte Sep. 30, 2024	
Company		Country	Cap. US\$M	US\$M	US\$M	Margin	2022	2023	EV/ EBITDA	E Rev
Medtronic plc	Medtronic	IRL	\$115,463	\$135,653	\$32,577	28.5%	23.3x	14.5x	14.6x	4
Merit Medical Systems, Inc.		USA	\$5,753	\$5,987	\$1,326	19.7%	23.0x	18.0x	22.9x	4
Owens & Minor, Inc.	Owens & Minor	USA	\$1,210	\$3,346	\$10,661	7.3%	8.3x	8.5x	4.3x	0
Sewoon Medical Co., Ltd	SEWOON MEDICAL CO.LTD	KOR	\$89	\$31	\$47	30.1%	10.8x	5.6x	2.2x	0.
Stryker Corporation	stryker	USA	\$137,667	\$148,454	\$21,974	25.7%	25.2x	21.2x	26.3x	6.
Teleflex Incorporated	Global Knowledge Network	USA	\$11,653	\$13,243	\$3,026	21.9%	27.4x	17.3x	20.0x	4.
West Pharmaceutical Services, Inc.	<b>West</b>	USA	\$21,774	\$21,642	\$2,876	28.0%	39.2x	25.0x	26.9x	7.
Excluded from mean and median						Mean	12.8x	12.7x	12.3x	2.
						Median	15.8x	15.2x	15.3x	3.







6.8x



7.5x



# Drug Stores Global Comparable Public Companies

Company		Country	try Cap. Value		Revenue EBITDA e US\$M Margin		Average BITDA	Third Quarte Sep. 30, 202		
Company		soundry	US\$M	US\$M	US\$M	Margin	2022	2023	EV/ EBITDA	E Rev
Corporativo Fragua, S.A.B. de C.V.	FRAGUA	MEX	\$4,414	\$4,229	\$6,012	5.6%	6.8x	7.8x	12.5x	0
CVS Health Corporation	<b>CVS</b> Health	USA	\$79,102	\$146,843	\$367,246	5.2%	8.8x	7.0x	7.6x	0.
Dimed S.A. Distribuidora de Medicamentos	DIMED	BRA	\$277	\$432	\$885	5.6%	11.6x	10.0x	8.7x	0
Empreendimentos Pague Menos S.A.	<b>Pague</b> Menos	BRA	\$279	\$912	\$2,233	6.6%	7.9x	7.5x	6.2x	0.
Farmacias Benavides, S.A.B. de C.V.	benavides.	MEX	\$418	\$593	\$904	10.6%	4.4x	4.8x	6.2x	0
Raia Drogasil S.A.	RaiaDrogasil S.A.	BRA	\$8,029	\$9,356	\$6,924	10.1%	15.3x	15.4x	13.3x	٦.
Walgreens Boots Alliance, Inc.	Walgreens Boots Alliance	USA	\$7,735	\$42,476	\$147,658	5.1%	7.9x	9.5x	5.6x	0
Excluded from mean and median						Mean	8.6x	8.4x	7.2x	0.
						Median	7.9x	7.8x	7.6x	0.





















# Pharmaceutical Products – Q3 Global Transactions (1/2)

Date	Target	Country	Description	Buyer	Seller	% Acquired	Size US\$M	EV/ EBITDA	Re
Sep-24	Worldwide Rights of DESFERAL®	CHE	<b>Mitem Pharma</b> , provider of medicines MITM, acquired <b>worldwide rights of DESFERAL</b> , injectable medicine for the treatment of iron overload, from Novartis, complementing its portfolio of MITMs	mitem pharma	<b>U</b> NOVARTIS	100.0%	-	-	
Sep-24 <sup>*</sup>	RLS (USA)	USA	<b>Telix</b> , provider of radiopharmaceuticals, agreed to acquire <b>RLS (USA)</b> , radiopharmacy network, expanding its manufacturing footprint and establishing a next-generation radiometal network	<b>()</b> Telix	RADIOPHARMACIES	100.0%	\$250.0	-	
Sep-24	& dermavant™	GBR	<b>Organon</b> , provider of women's healthcare products, acquired <b>Dermavant</b> , developer of dermatologic therapies, expanding its dermatology portfolio with VTAMA® (tapinarof) cream	- CRGANON	-	100.0%	\$1,486.0	-	
Sep-24 <sup>*</sup>	VECTURA	GBR	Molex Asia Holdings, provider of electronics and connectivity solutions, agreed to acquire <b>Vectura</b> , provider of pharmaceutical therapies, from Vectura Fertin Pharma, enhancing its product portfolio	molex	Vectura Fertin Pharma	100.0%	\$392.4	-	
Sep-24	Seaview Enterprises	USA	Hims & Hers, telehealth company, acquired Seaview Enterprises, provider of generic prescription medicines, from Nivagen, enhancing its manufacturing capabilities	hims & hers	NIVAGEN	100.0%	\$28.8	-	
Aug-24	PHARMACEUTICALS	USA	<b>KE Manufacturing</b> , provider of human capital management solutions, merged with <b>Titan</b> , manufacturer of biopharmaceutical products, enhancing Titan's strategic direction by integrating KE's expertise in human capital management	K.E.Manufacturing Sdn. Bhd.	-	Merger	\$21.6	-	







# Pharmaceutical Products – Q3 Global Transactions (2/2)

Date	Target	Country	Description	Buyer	Seller	% Acquired	Size US\$M	EV/ EBITDA	Re
Aug-24	REVANCE THERAPEUTICS	USA	<b>Crown</b> , manufacturer of skincare products, merged with <b>Revance Therapeutics</b> , manufacturer of neuromodulator offerings, aiming to become a fully integrated global aesthetics and skincare company	C R O W N'	-	Merger	\$1,212.4	-	
Aug-24 <sup>*</sup>	<b>Therakos</b> <sup>®</sup> ECP Immunomodulation	FRA	<b>CVC</b> , private equity firm, agreed to acquire <b>Therakos</b> , provider of extracorporeal photopheresis (ECP) systems, from Mallinckrodt, expanding its healthcare portfolio	CVC CAPITAL PARTNERS	Mallinckrodt	100.0%	\$925.0	-	
Jul-24	IRONSHORE PHARMACEUTICALS	CAN	<b>Collegium</b> , specialty pharmaceutical company focused on pain management, acquired <b>Ironshore</b> , provider of ADHD treatments, expanding its portfolio into neurology and establishing a presence in the ADHD market	Collegium.	-	100.0%	\$525.0	-	
Jul-24 <sup>*</sup>	HEPION PHARMACEUTICALS	USA	<b>Pharma Two B</b> , provider of Parkinson's disease products, agreed to merge with <b>Hepion</b> , provider of biopharmaceutical products, facilitating Pharma Two B's public market entry and advancing P2B001's development	Pharma Two B	-	Merger	\$58.5	-	
Jul-24	VALINOR	USA	<b>Grünentha</b> l, provider of pain management solutions, acquired <b>Valinor</b> , provider of Movantik® (naloxegol), strengthening its U.S. presence and becoming the global owner of Movantik®	GRÜNENTHAL	-	100.0%	\$250.0	-	
Jul-24	Womens Health Specialty Business	USA	<b>Evofem Biosciences</b> , provider of biopharmaceutical products for women's health, acquired <b>Women's Health Specialty Business from Lupin</b> , expanding its portfolio and strengthening its position in women's health	E OFEM BIOSCIENCES <sup>®</sup>	HARMACEUTICALS, INC.	100.0%	\$84.0	-	
*Announce	ed transactions pendina	approval an	d other closing conditions				Mean	_	

\*Announced transactions pending approval and other closing conditions

- Mean
- Median -







1.6x

# Medical Equipment - Q3 Global Transactions (1/3)

Date	Target	Country	Description
Sep-24	⊘ <b>spire</b> health	USA	<b>Wellinks Inc</b> , provider of digital healthcare solutions, acquired <b>Spi</b> health-tracking devices and remote patient monitoring solutions, creating a fully integrated "predictive patient care" company
Sep-24	oventure	ESP	<b>Austell</b> , pharmaceutical company, acquired <b>Noventure</b> , provider of devices, from Grupo Ferrer, enhancing its portfolio in gastroentero pediatrics, and dermatology
Sep-24	MORGAN	USA	<b>Vitalograph</b> , provider of respiratory diagnostic solutions, acquired customer-facing software for advanced pulmonary function testin strengthening its commercial footprint
Sep-24	gri. THINK. MAKE. PROTECT.	USA	<b>Winner</b> , manufacturer of wound care and surgical Products acqui <b>Resources International</b> , manufacturer of healthcare equipment, internationally
Sep-24	ovizio	BEL	<b>ChemoMetec</b> , manufacturer of instruments for cell counting, acquimanufacturer of digital holographic interferometric microscopy product portfolio
Sep-24 <sup>*</sup>		DEU	<b>German-American consortium</b> agreed to acquire <b>Apoplex Medic</b> manufacturer of medico-technical instruments and supplies, from realigning its operations
Sep-24 <sup>*</sup>	<b>BIOLASE</b> LEADER IN DENTAL LASERS <sup>®</sup>	USA	<b>Sonendo</b> , provider of the GentleWave® System, agreed to acquire of dental laser systems, enhancing its technology platform

	Buyer	Seller	% Acquired	Size US\$M	EV/ EBITDA	Re
<b>pire Health</b> , provider of s, from Gilde Healthcare,		HEALTHCARE PARTNERS	100.0%	-	-	
r of licensing medical rology, urogynecology,	Medicine with a conscience	🚺 ferrer	100.0%	-	-	
ed <b>Morgan</b> , provider of ing (PFT) systems,	Malograph	-	100.0%	-	-	
uired a stake in <b>Global</b> t, expanding	winner	-	75.2%	\$120.0	7.8x	
quired <b>Ovizio</b> , products, increasing its	chemometec	-	100.0%	\$3.2	-	
<b>ical Technologies</b> , m Geratherm,	German-American consortium	Geratherm®	60.6%	\$18.3	-	
re <b>Biolase</b> , manufacturer	Saving teeth. Restoring health.	-	100.0%	\$14.0	-	











# Medical Equipment - Q3 Global Transactions (2/3)

Date	Target	Country	Description
Sep-24	MEDICA NUTRINIEN CONCENSION	USA	<b>Nihon Kohden</b> , manufacturer of medical devices, acquired a stake of specialized electrodes for neurodiagnostic procedures, from Arc neurology portfolio
Sep-24	Osteotomy Truss System and Ankle Truss System	USA	<b>Stryker</b> , provider of medical technologies, acquired the <b>Osteotom</b> <b>Ankle Truss System</b> , providers of healthcare products, reflecting is providing surgeons with enhanced orthopedic solutions
Sep-24	Quality products for life	USA	<b>Veridian Healthcare</b> , provider of diagnostic products, acquired <b>Ze</b> telehealth and remote patient monitoring devices, positioning as diagnostic medical and telehealth products in North America
Aug-24	Vertos	USA	<b>Stryker</b> , provider of medical technologies, acquired <b>Vertos Medica</b> devices, primarily minimally invasive treatments for lumbar spinal its interventional pain management portfolio
Aug-24	PARAGONIX	USA	<b>Getinge</b> , provider of medical technology, acquired <b>Paragonix</b> , pro- transport products, enhancing its portfolio in organ preservation a
Aug-24 <sup>*</sup>	Vantive	NLD	The Carlyle Group and Atmas Health, investment firms, agreed to Health, provider of kidney care equipment, from Baxter, aiming to into a standalone global business
Aug-24	simple, bright ideas.	USA	<b>Cooper Surgical</b> , provider of women's health and fertility solutions <b>Surgical</b> , provider of surgical retractors with integrated multi-LED evacuation channels, providing clinicians with a broader range of s

	Buyer	Seller	% Acquired	Size US\$M	EV/ EBITDA	Re
ke in <b>Ad-Tech</b> , provider Archimed, enhancing its	<b>NIHON KOHDEN</b>	ARCHIMED	71.4%	-	-	
<b>my Truss System and</b> g its commitment to	stryker	<b>4VEB</b> MEDICAL	100.0%	-	-	
<b>Zewa</b> , provider of as a leading supplier in		-	100.0%	-	-	
<b>ical</b> , provider of medical al stenosis, enhancing	stryker	_	100.0%	-	-	
rovider of organ n and transportation	getinge 🛠	SIGNET Healthcare Partners	100.0%	\$477.0	-	
to acquire <b>Vantive</b> to transform Vantive		Baxter	100.0%	\$3,800.0	-	
ns, acquired <b>Obp</b> D light and dual smoke of surgical technologies	CooperSurgical®	-	100.0%	\$100.0	-	









# Medical Equipment - Q3 Global Transactions (3/3)

Date	Target	Country	Description
Jul-24	precision surgery made simpler®	CAN	<b>Stryker</b> , provider of medical technologies, acquired <b>MOLLI</b> , manuf soft tissue localization systems, enhancing its solutions portfolio in
Jul-24	JENAVALVE	USA	<b>Edwards Lifesciences</b> , provider of heart disease and critical care n agreed to acquire <b>JenaValve</b> , manufacturer of transapical transcar implantation systems, expanding its portfolio offering
Jul-24 <sup>*</sup>	ENDOTRONIX	USA	<b>Edwards Lifesciences</b> , provider of heart disease and critical care nagreed to acquire <b>Endotronix</b> , manufacturer of implantable pressents structural heart portfolio
Jul-24 <sup>*</sup>	ROTECH <sup>®</sup> HEALTHCARE INC.	USA	<b>Owens &amp; Minor</b> , provider of healthcare solutions, agreed to acquir manufacturer of home medical equipment, enhancing its patient
Jul-24 <sup>*</sup>		USA	<b>Astorg</b> , private equity firm, agreed to acquire <b>Hamilton Thorne</b> , m precision instruments, laboratory equipment, consumables, softw creating a comprehensive provider of high-quality equipment
Jul-24	Sleep Testing Diagnostic Technology	USA	<b>EnsoData</b> , provider of healthcare technology, acquired <b>sleep testi</b> <b>technology from Resonea</b> , provider of sleep diagnostic devices, er data-driven approach to pre-screening patients
Jul-24	AJR ENTERPRISES	USA	<b>UFP Technologies</b> , manufacturer of solutions for medical devices, <b>Enterprises</b> , manufacturer of single-use safe patient handling syst patient surfaces portfolio

\*Announced transactions pending approval and other closing conditions

	Buyer	Seller	% Acquired	Size US\$M	EV/ EBITDA	R
ufacturer of wire-free in breast cancer care	stryker	-	100.0%	-	-	
e monitoring equipment, catheter aortic valve	E Edwards Lifesciences	-	100.0%	\$945.0	-	
e monitoring equipment, ssure sensors, expanding	É Edwards Lifesciences	-	100.0%	\$675.0	-	
uire <b>Rotech Healthcare</b> , nt direct segment	Owens & Minor*	-	100.0%	\$1,320.0	6.3x	
manufacturer of ware, and services,	ostorg.	-	100.0%	\$282.0	-	
<b>sting diagnostic</b> enabling a mobile-first,	Šensodata	RESONEA	100.0%	-	-	
es, acquired <b>AJR</b> vstems, enhancing its	UFP TECHNOLOGIES	-	100.0%	\$120.8	6.6x	
				Mean	6.9x	
				Median	6.6x	











#### 1.6x

1.2x 1.3x

# Hospitals – Q3 Global Transactions (1/2)

Date	Target	Country	Description	Buyer	Seller	% Acquired	Size US\$M	EV/ EBITDA	l Rev
Sep-24	Fort Myers Healthcare Facilities	USA	<b>Sila Realty Trust</b> , real estate investment trust, sold the <b>Fort Myers Healthcare Facilities</b> , two vacant properties formerly leased to GenesisCare, aiming to streamline its portfolio and reallocate capital	-	realty trust	100.0%	\$15.5	-	
Sep-24	29-Property Skilled Nursing Portfolio in Iowa	USA	<b>Cascade Capital Group</b> , private equity firm, acquired <b>29 long-term care properties in</b> <b>Iowa</b> , from ABCM, expanding its presence in the healthcare real estate sector	CASCADE CAPITAL GROUP	ABCM Corporation www.abcmcorp.com	100.0%	\$85.0	-	
Aug-24	Good Samaritan and St. Elizabeth's Medical Center	USA	Boston Medical Center, academic healthcare system, acquired Good Samaritan Medical Center and St. Elizabeth's Medical Center, from Steward Health Care System, increasing capabilities	EXCEPTIONAL CARE. WITHOUT EXCEPTION.	© Steward Steward Health Care System	100.0%	-	-	
Aug-24 <sup>*</sup>	REGIONAL MEDICAL CENTER	USA	<b>County of Santa Clara</b> , provider of healthcare services, agreed to acquire <b>Santa Regional</b> <b>Medical Center (RMC)</b> , acute-care hospital, reinforcing healthcare access in East San Jose	County of Santa Clara	HCA* Healthcare®	100.0%	\$175.0	-	
Aug-24	Morton and Steward St. Anne's Hospitals	USA	<b>Lifespan Corporation</b> , provider of healthcare services in Rhode Island, acquired <b>St.</b> <b>Anne's Hospital and Morton Hospital</b> , from Steward Health Care, enhancing its Massachusetts healthcare footprint and service offerings	Lifespan Delivering health with care*	© Steward Steward Health Care System	100.0%	\$175.0	-	
Aug-24	11 Healthcare Facilities in Colorado	USA	<b>UCHealth</b> , nonprofit health system in Colorado, acquired <b>11 healthcare facilities</b> , from Medical Properties Trust, enhancing its statewide outpatient services portfolio	uchealth	Medical Properties Trust	100.0%	\$86.0	-	







# Hospitals - Q3 Global Transactions (2/2)

Date	Target	Country	Description	Buyer	Seller	% Acquired	Size US\$M	EV/ EBITDA	Re
Aug-24 <sup>*</sup>	revere medical	USA	<b>Rural Healthcare Group (RHG)</b> , provider of healthcare services, agreed to acquire <b>Stewardship</b> , provider of physician-led multispecialty services now known as Revere Medical, expanding its national footprint	rural healthcare group	© Steward Steward System	100.0%	-	-	
Aug-24	Medical facility in Florida	USA	<b>Global Medical REIT</b> , real estate investment trust, sold a medical facility in Panama City, Florida, resulting in a \$1.7 million gain, as part of its capital recycling plan	_	GLOBAL MEDICAL REIT	100.0%	\$49.5	-	
Aug-24	<b>Brookwood Baptist</b> Health.	USA	<b>Orlando Health</b> , provider of healthcare services, acquired a 70% stake in <b>Brookwood</b> <b>Baptist Health</b> , network of hospitals, from Tenet Healthcare, adding five Birmingham- area hospitals and expanding into Alabama	<b>ORLANDO HEALTH</b> °	<b>Tenet</b> Health	70.0%	\$910.0	-	
Aug-24	53 Nursing facilities	CAN	Pacs Group, investment compnay, acquired <b>53 skilled nursing, assisted, and</b> independent living facilities, from Prestige Care, extending its footprint	PACS	-	100.0%	\$43.0	-	
Jul-24	Fort Smith Inpatient Rehabilitation Facility	USA	<b>Sila Realty Trust</b> , real estate investment trust, acquired a <b>50-bed rehabilitation facility</b> in Fort Smith, Arkansas, enhancing its healthcare portfolio	realty trust	-	100.0%	\$28.3	-	
Jul-24	8 Arizona Facilities	USA	<b>Dignity Health</b> , provider of health care services, acquired <b>8 Arizona facilities</b> , from Medical Properties Trust, expanding capabilities	Straight Straight Bealth	Medical Properties Trust	100.0%	\$160.0	-	

\*Announced transactions pending approval and other closing conditions







# Drug Stores – Q3 Global Transactions

Date	Target	Country	Description	Buyer	Seller	% Acquired	Size US\$M	EV/ EBITDA	Re
Sep-24	Pharmacy business	CAN	<b>PharmaCorp</b> , pharmacy chain, acquired pharmacy business including land and buildings in Canada, boosting growth	PharmaCorp 🔗	-	100.0%	#VALUE!	-	
Sep-24	Farmacia desde 1910	URY	<b>Farmashop</b> , pharmacy chain, acquired <b>Farmacia Pasteur</b> , century-old phamacy chain operating five stores, expanding its presence beyond Montevideo	farmashop Lecuida	-	100.0%	-	-	
Sep-24	C&R Pharmacy	USA	<b>Waverley Pharma</b> , provider of therapeutics, acquired <b>C&amp;R Pharmacy</b> , an independent pharmacy in Ohio, generating immediate revenue and supporting local community healthcare	Waverley Pharma	-	100.0%	\$0.5	-	
Sep-24 <sup>*</sup>	Rexall	CAN	<b>Birch Hill</b> , private equity firm, agreed to acquire <b>Rexall Pharmacy Group</b> , pharmacy chain with 385 locations, strengthening its presence in the Canadian healthcare market	BIRCH HILL equity partners	MCKESSON Canada	100.0%	-	-	
Aug-24	Desde 1891 La Danesa FARMACIAS	ARG	<b>FarmaPlus</b> , pharmacy chain operating in Buenos Aires and its suburbs, acquired <b>Farmacia La Danesa</b> , retailer pharmacy with four locations in the Belgrano neighborhood, strengthening its presence in the city	FarmaPlus	-	100.0%	\$4.5	-	
Aug-24	VFP PHARMACY GROUP	USA	<b>BelHealth Investment Partners</b> , private equity firm, divested <b>VFP Pharmacy Group</b> , national fertility pharmacy, after growing its revenues fivefold through organic growth and strategic acquisitions	-	BELHEALTH Investment Partners	100.0%	-	-	
Jul-24	HomeFree PHARMACY SERVICES	USA	<b>AnewHealth</b> , pharmacy care management provider, acquired <b>HomeFree Pharmacy,</b> provider of pharmacy services, strengthening dedication to delivering a comprehensive level of medication-related care	<b>/ anew</b> health	-	100.0%	-	-	
Jul-24	KEYSTONE SPECIALTY PHARMACY A NEW APPROACH	USA	Novastone Capital Advisors, private equity firm, acquired Keystone Specialty Pharmacy, specialty pharmacy, enhancing its healthcare portfolio	NOVASTONE CAPITAL ADVISORS	-	100.0%	-	-	
*Announce	ed transactions pending o	approval an	d other closing conditions				Mean Median	-	









# 

#### TARGET Sensi-Care and Aloe Vesta

#### **TRANSACTION TYPE** Sell-side Advisory

#### INDUSTRIES

Healthcare, Personal Care

#### GEOGRAPHY Reading, GBR

#### **SITUATION**

Seale & Associates acted as financial advisor to ConvaTec Group (LON: CTEC) on the divesture of Sensi-Care and Aloe Vesta to Medline Industries. ConvaTec Group (LON: CTEC), is a global medical products company based in the United Kingdom.

#### **SEALE & ASSOCIATES' APPROACH**

Seale managed a competitive auction process with potential strategic and financial buyers for Sensi-Care and Aloe Vesta. Seale's disciplined approach allowed our client to maintain momentum, negotiating leverage throughout the process and ensure closing at a premium value and more favorable terms.

#### OUTCOME

The process resulted in a successful acquisition of Sensi-Care and Aloe Vesta by Medline Industries, a healthcare company with almost USD\$14 billion in annual sales. The divestiture is part of ConvaTec's strategy to focus on its core businesses and markets.

#### HEALTHCARE Q3 2024



"Seale was instrumental in keeping the process moving in a swift, orderly fashion"



"Seale was instrumental in keeping the process moving in a swift, orderly fashion. Their common sense and ability to find simple, common ground solutions while preserving our interests were invaluable in bringing this project to a successful conclusion."

George Landau, Vice President of Corporate **Development** at ConvaTec

# 

#### TARGET Laboratorios Portugal S.R.L

#### **TRANSACTION TYPE** Acquisition Advisory

#### INDUSTRIES

Healthcare, Pharmaceutical

#### GEOGRAPHY Peru

#### **SITUATION**

Seale & Associates acted as exclusive financial advisor to Invekra, assisting with comprehensive research on the Peruvian pharmaceutical market and the prioritization of potential acquisition targets.

#### **SEALE & ASSOCIATES' APPROACH**

Seale completed a thorough screening of the potential universe of pharmaceutical companies that would align with Invekra's strategy. Seale pre-qualified each potential target and initiated transaction discussions with the targets that best fit Invekra's strategy and investment criteria.

#### OUTCOME

The process resulted in a successful acquisition of Laboratorios Portugal S.R.L by Invekra, a conglomerate of 12 Latin American pharmaceutical companies. The acquisition strengthens Invekra's presence in Latin America.

#### HEALTHCARE Q3 2024

**"This acquisition strengthens** Invekra's presence in one of the fastest growing markets in Latin America"



"This acquisition strengthens Invekra's presence in one of the fastest growing markets in Latin America."

Carlos Hernández Goudet, Managing Director at Seale & Associates

# Sign up for M&A insights

We deliver sector-specific intelligence designed specifically for industry leaders, private equity firms, and their advisors. Our industry reports and featured articles deliver real-time access to key industry data, including:



#### Emerging industry trends

Quarterly reports covering 30+ industries Monthly reports for the U.S., Mexico, and Colombia

Transaction analysis and market trends

Valuable insights for industry leaders

#### Receive email updates with our proprietary data, reports, and insights as they are published for the industries that matter to you the most

SUBSCRIBE







# **Global M&A Representative Engagements**









#### **JAMES A. SEALE**

President and Founder | Washington, DC



32+ years of global M&A experience, Attorney, CPA Arthur Andersen, and Professor of Global Investment Banking at George Washington University University of Virginia - JD University of Kentucky - BS in Accounting



#### **SERGIO GARCIA DEL BOSQUE**

Managing Director | Mexico City, Mexico



+52 (55) 8000-7463

16+ years of global M&A experience IPADE - MBA Instituto Tecnologico y de Estudios Superiores de Monterrey BS in Industrial Engineering



#### **CARLOS HERNANDEZ GOUDET**

Managing Director | San Luis Potosi, Mexico



14+ years of global M&A experience Columbia University - MBA Instituto Tecnologico y de Estudios Superiores de Monterrey BS in Industrial Engineering







Please contact us if you would like further information about M&A trends and/or specific transaction multiples for your industry. © Seale & Associates



#### **BRETT M. CARMEL**

Senior Managing Director and Co-founder | Miami, FL

+1 (703) 294-6530 

25+ years of global M&A experience and Professor of M&A at Johns Hopkins University

The George Washington University - MBA International Business and MA - International Affairs

University of Florida - BA in Political Science with High Honors



#### **ROBERT E. WHITNEY**

Managing Director | Washington, DC

+1 (703) 801-8939

19+ years of global M&A experience, CPA Deloitte & Touche, Corporate Audit and Assurance Services University of Richmond - BS Business Administration in Accounting



#### **FELIPE BUENO**

Senior Director | Monterrey, Mexico



+52 (84) 4432-4444

32+ years with Grupo Industrial Saltillo with experience as Director, Corp. Dev. and extensive global commercial experience Instituto Tecnologico y de Estudios Superiores de Monterrey MBA and BS in Industrial Engineering

Monterrey





### **Creative Solutions.** Trusted Advice.

For over 25 years, Seale & Associates has served leading public and private companies from around the world and operating in a broad range of industries with a high level of quality, integrity and independence while presenting innovative ideas and trusted solutions to address their most complex dealings.



YEARS OF **EXPERIENCE**  \$50B+

TRANSACTIONS GLOBALLY

# **Trusted Advisor to Leading Companies Worldwide**

We have worked repeatedly with many of the most well-



#### **SERVICES AND SOLUTIONS**

Mergers & Acquisitions	Due Diligence / Support
Divestitures	Expert Witness Testimony
Joint Ventures / Alliances	Corporate Finance Adviso
Recapitalizations	Strategy Consulting





# Seale & Associates Creative Solutions. Trusted Advice.

